FDA approves skin cancer vaccine by...?
9 signals across 1 market · $16,235 tracked · resolves Jan 1, 2028
This Polymarket event tracks whether the FDA approves intismeran autogene, an individualized neoantigen therapy from Moderna and Merck, for any indication by December 31, 2027. PolySpotter is tracking $2,727 in smart money across the event, including a recent alert for serial sharp exits from Yes positions.
Markets (1)
Top trades across all markets
- Serial sharp exits Yes
A proven, serial cross-market bettor made a sizable bearish move in a thin market, though the trade appears to be closing an existing Yes position rather than opening a fresh one.
$2,727Wallet win rate: 80%Score: 5.4 - Serial sharp exits Yes
A proven, serial cross-market bettor made a sizable bearish move in a thin market, though the trade appears to be closing an existing Yes position rather than opening a fresh one.
$1,188Wallet win rate: 80%Score: 5.1 - Sharp bettor scales into No
A historically profitable serial cross-market bettor added $2,298 to No at roughly 35¢ in a thin market, reinforcing an existing position.
$2,298Wallet win rate: 80%Score: 5.1 - Profitable serial cross-market trader
A highly active cross-market trader with substantial lifetime profit has opened a No position at 37¢, though their overall win rate does not clearly beat the odds they typically pay.
$1,204Wallet win rate: 82%Score: 4.7 - Serial sharp exits Yes
A proven, serial cross-market bettor made a sizable bearish move in a thin market, though the trade appears to be closing an existing Yes position rather than opening a fresh one.
$1,110Wallet win rate: 80%Score: 4.7 - Serial cross-market winner backs No
A highly experienced, strongly profitable cross-market trader bought No at 35¢, and the position is now marked near 50¢ in a thin market.
$3,101Wallet win rate: 82%Score: 4.7 - Serial cross-market winner backs No
A highly experienced, strongly profitable cross-market trader bought No at 35¢, and the position is now marked near 50¢ in a thin market.
$1,167Wallet win rate: 82%Score: 4.3 - Profitable serial cross-market trader
A highly active cross-market trader with substantial lifetime profit has opened a No position at 37¢, though their overall win rate does not clearly beat the odds they typically pay.
$1,287Wallet win rate: 82%Score: 4.3 - Serial cross-market winner backs No
A highly experienced, strongly profitable cross-market trader bought No at 35¢, and the position is now marked near 50¢ in a thin market.
$2,153Wallet win rate: 82%Score: 4.0
Top wallets in this event
- 0x5188fa…c804$8,912 · 1 market · 5 alerts · 82% wins
- 0x277989…239a$7,324 · 1 market · 4 alerts · 80% wins
FAQs
What are the Polymarket odds for FDA approval of the skin cancer vaccine?
The event tracks a Yes-or-No market on FDA approval of intismeran autogene by December 31, 2027. Current odds are shown on the PolySpotter event page and may change as traders buy and sell positions.
What is the skin cancer vaccine FDA approval prediction market?
It is a Polymarket prediction market asking whether the FDA grants approval to intismeran autogene, also known as mRNA-4157 or V940, for any indication by 11:59 PM ET on December 31, 2027.
What is smart money doing in this event?
PolySpotter tracks $2,727 in smart money across the event and one signal. The latest alert headline reports serial sharp exits from Yes positions, meaning tracked sharp traders have recently been exiting those positions.
What is intismeran autogene?
Intismeran autogene is an individualized neoantigen therapy developed by Moderna and Merck. It has been evaluated in the Phase 3 INTerpath-001 trial and is also known as mRNA-4157 or V940.
When does this FDA approval market resolve?
The market resolves Yes if the FDA approves intismeran autogene for any indication by December 31, 2027, at 11:59 PM ET. Otherwise, it resolves No.